.png)
To analyze and assess the safety and efficacy of dupilumab as an adjuvant treatment for chronic rhinosinusitis with nasal polyposis. Two authors independently searched 6 databases from inception until May 2021. We included and analyzed studies comparing dupilumab-treated (dupilumab) and placebo-treated (control) groups. The risk of bias was evaluated using the Cochrane Risk of Bias tool. Three studies, including 784 participants, were included. The dupilumab group showed significantly improved laboratory markers in serum and nasal secretions compared to the control group except for serum eosinophils. In addition, dupilumab showed higher efficacy for olfactory symptoms, disease-related symptoms (nasal congestion, sinusitis symptom severity, nasal polyp score), and radiologic findings (computed tomography score). However, there were no significant differences in treatment-related morbidities between the 2 groups. According to a meta-analysis of studies reporting laboratory and clinical results, dupilumab is a safe and effective treatment for patients suffering from chronic rhinosinusitis with nasal polyps.
Cite this article as: Hyun Kim D, Won Kim S, Basurrah MA, Hwan Hwang S. The safety and efficacy of dupilumab for chronic rhinosinusitis with nasal polyposis: A meta-analysis. B-ENT. 2023;19(2):118-126.